CGP-53353
CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients[1].
Product Specifications
CAS Number
145915-60-2
Product Name Alternative
DAPH-7
UNSPSC
12352005
Target
DNA/RNA Synthesis; PKC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/cgp-53353.html
Concentration
10mM
Purity
98.87
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C1NC(C2=C1C=C(NC3=CC=C(F)C=C3)C(NC4=CC=C(F)C=C4)=C2)=O
Molecular Formula
C20H13F2N3O2
Molecular Weight
365.33
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PKCβ
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HSPC302 (TBCK) (NM_001163437) Human Tagged ORF Clone Lentiviral Particle
